Search PubMed⌕ Search

Biomedical subjects

E Streicher

Publications and source records attributed to E Streicher.

At least 19 recordsLinked to original sources
PubMed1985

[Arterial hypertension in renin-producing retroperitoneal leiomyosarcoma].

A case report of an extrarenal retroperitoneal metastatic leiomyosarcoma with associated paraneoplastic renin production is presented. Due to the renin excess syndrome, accelerated hypertension was present combined with the signs of secondary hyperaldosteronism, hypokalemia, and alkalosis. In contrast to other publications of extrarenal malignoma with paraneoplastic renin activity, this case elucidates a histologically close relationship to epitheloid muscle cells of kidney vasa afferentia and derived benign tumors. The retroperitoneal tumor and its brain metastase were morphologically identical. In contrast to histological criteria only the primary tumor exhibited high renin activity, no activity could be detected in the metastase.

Adult↗
PubMed1985

The isolation and characterization of pepsinogens from the proventriculus of the ostrich Struthio camelus.

Three pepsinogens were isolated and purified from the proventriculus of the ostrich Struthio camelus, by a combination of chromatography steps on DEAE-cellulose, Sephadex G-100 and Hydroxylapatite. The purified pepsinogens manifested peptic activity towards haemoglobin as substrate after activation, but resembled chicken pepsinogens in that they appeared to lose their potential peptic activities during storage. All three pepsinogens contained glycine as N-terminal amino acid, but differed in their overall amino acid compositions. The pH and temperature optima of the activated pepsinogens were determined, as well as their molecular weights.

Amino Acids↗
PubMed1985

Mass transfer characterization of a new polysulfone membrane.

A new polysulfone capillary membrane has been tested ex vivo for its clearance performance under diffusive, combined diffusive and convective, and pure convective solute mass transfer. As was expected, increasing convective mass transfer produced augmentation only of clearances of high molecular weight solutes, and to a much lesser extent than reported for other membranes. This behavior is explainable by the enormous diffusive clearance capacity of the new membrane, which nearly reaches its theoretical maximal value, as derived from a computer model. Based on the very high hydraulic permeability, which makes this membrane equally suitable for filtrative and diffusive procedures, no membrane solute retention was found up to a molecular weight of 5,000 daltons. Stable hemocompatibility parameters (leukocytes, thrombocyte, and complement measurements) demonstrated absence of activation by this membrane during treatment. It is concluded that since its clearance performance is near the theoretical maximal and it shows superior biocompatibility, the membrane exhibits negligible interaction with the transported solutes independent of the transport mode.

Blood↗
PubMed1985

Aluminum-free oral phosphate binder.

For the purpose of intestinal phosphate binding we have developed aluminum free substances. These substances are natural polymers consisting of heteropolyuronic acid charged with different cations. The in vitro experiments showed an efficacy 2 to 3 times greater than Aludrox. During the clinical application, up to one year, no serious side effects have been detected. Serum phosphate levels could not be lowered in all patients to the desired level of 5 mg% mainly due to problems in patients compliance and to low dosage of the prescribed phosphate binder.

Administration, Oral↗
PubMed1984

[Hemodynamics during hemodialysis, hemofiltration and hemodiafiltration using bicarbonate vs acetate buffers].

Hemodynamic parameters of five chronic renal failure patients have been compared intraindividually during hemodialysis, hemofiltration, and hemodiafiltration using either acetate or bicarbonate buffer. During acetate dialysis symptomatic hypotensive episodes were common. During hemofiltration with acetate buffering a satisfactory hemodynamic stability was maintained. Cardiac and circulatory compensation was found superior with bicarbonate buffering irrespective of the treatment mode.

Acetates↗
PubMed1983

High-effective aluminium free phosphate binder. In vitro and in vivo studies.

For the purpose of intestinal phosphate binding we have developed aluminium free natural polymers consisting of heteropolyuronic acid charged with different cations. The in vitro experiments showed an efficacy two to three times greater than Aludrox. During up to six months of clinical application no serious side effects have been detected, constipation ceased and serum phosphate was maintained in an acceptable range.

Humans↗
PubMed1981

Ferritin: a reliable indicator of iron supplementation in patients on chronic hemodialysis/hemofiltration treatment?

Four hundred and forty-two serum ferritin determinations were performed in 144 patients on chronic intermittent hemodialysis treatment with intravenous iron substitution and/or oral iron substitution. Iron substitution should be done individually according to regular serum ferritin determinations. Intravenous iron substitution is easier to regulate. Iron substitution exceeding 100 mg per month normally leads to a slowly progressing iron overload except in those patients with additional blood loss or on chronic hemofiltration treatment. Iron administration should not be evaluated according to ferritin levels in patients with additional complications such as active hepatitis, tumors, infectious diseases, and operations. In these cases evaluation of iron storage can only be estimated by bone marrow examination.

Administration, Oral↗
PubMed1980

Chronic hemofiltration treatment.

Fourteen patients (six males and eight females) have been treated with chronic hemofiltration three times weekly for three to 27 months with the post-dilution technique. All patients had previously been on regular dialysis treatment. Patients were selected for hemofiltration because of dialysis-resistent hypertension (eight), symptoms of dialysis discomfort (five), hypertriglyceridemia (five) and polyneuropathy (seven). Hypertension improved in six of eight patients, symptoms of dialysis discomfort markedly diminished in all five patients, hypertriglyceridemia did not change consistently, polyneuropathy improved in six of seven patients. Balance studies of Na, Ca and Mg revealed a positive correlation to fluid balance. Phosphate, BUN, creatinine and uric acid increased. Loss of amino acids and protein is negligible. Hormone studies showed a decrease of T3, T4 and TSH though the pituitary-thyroid axis is intact, possibly indicating a decreased TRH activity. Vitamin D remained unchanged, PTH levels increased, possibly related to a diminished excretion of phosphate and diminished intake of calcium, respectively, during hemofiltration treatment as compared to hemodialysis.

Acid-Base Equilibrium↗
PubMed1980

Hemofiltration and plasma dopamine beta-hydroxylase activity.

Plasma dopamine beta-hydroxylase (DBH) activity was studied in control patients (n = 70), in patients on maintenance hemodialysis (n = 79) and in patients on maintenance hemofiltration (n = 19). DBH activity was significantly lower in patients on hemodialysis (32.4 +/- 20.6 IU) and hemofiltration (32.8 +/- 29.7 IU) than in control individuals (50.0 +/- 29.3 IU). Sequential measurements of DBH in patients on maintenance hemofiltration failed to show a fall of plasma DBH with time. 7 patients were studied during one session of hemodialysis and one session of hemofiltration. External fluid balance was identical. The change of DBH during hemodialysis and hemofiltration was not significantly different. Such rise of DBH as occurs may entirely be accounted for by hemoconcentration.

Adult↗